Cargando…

Olanzapine versus aprepitant for the prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients receiving doxorubicin-cyclophosphamide regimen: A prospective, nonrandomized, open-label study

OBJECTIVE: Despite the guideline-directed therapy, complete absence of nausea was noted only in 33% of breast cancer patients on anthracycline-cyclophosphamide regimen. Hence, we sought to compare the efficacy of aprepitant (APT) versus olanzapine (OLP) in preventing chemotherapy-induced nausea and...

Descripción completa

Detalles Bibliográficos
Autores principales: Shivaprakash, G., Udupa, Karthik S., Sarayu, V., Thomas, Joseph, Gupta, Vishal, Pallavi, L. C., Pemminati, Sudhakar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5892027/
https://www.ncbi.nlm.nih.gov/pubmed/29674800
http://dx.doi.org/10.4103/ijp.IJP_846_16
_version_ 1783313101172506624
author Shivaprakash, G.
Udupa, Karthik S.
Sarayu, V.
Thomas, Joseph
Gupta, Vishal
Pallavi, L. C.
Pemminati, Sudhakar
author_facet Shivaprakash, G.
Udupa, Karthik S.
Sarayu, V.
Thomas, Joseph
Gupta, Vishal
Pallavi, L. C.
Pemminati, Sudhakar
author_sort Shivaprakash, G.
collection PubMed
description OBJECTIVE: Despite the guideline-directed therapy, complete absence of nausea was noted only in 33% of breast cancer patients on anthracycline-cyclophosphamide regimen. Hence, we sought to compare the efficacy of aprepitant (APT) versus olanzapine (OLP) in preventing chemotherapy-induced nausea and vomiting (CINV) in breast cancer patients on doxorubicin-cyclophosphamide regimen. PATIENTS AND METHODS: A prospective, open-label, nonrandomized study was conducted at the Department of Oncology. Eighty-three patients completed the study with 43 in the APT group and 40 in OLP group. Data about nausea and vomiting were collected using Multinational Association of Supportive Care in Cancer Antiemesis Tool (MAT). The severity of nausea and vomiting was assessed by the MAT and Common Terminology Criteria for Adverse Events (CTCAE) version 4.03, respectively. RESULTS: Complete response (no emesis and no rescue medication) was achieved in 81% of the patients in APT group and 85% in the OLP group in the acute period (P = 0.661); 74% of patients in APT group and 85% in OLP group had no nausea during the same period (P = 0.233). Among the OLP patients who had nausea, 67% had moderately severe and 33% had Severe grade, and in the APT group, severity was equally distributed in mild, moderate, and severe grades. Among the patients who had vomiting, severe (CTCAE) vomiting was noticed in 81% of patients who were treated with APT compared to 50% in OLP group. CONCLUSION: OLP was found to be an equally effective alternative to APT in the antiemetic prophylaxis of CINV in breast cancer patients receiving chemotherapy with doxorubicin-cyclophosphamide regimen.
format Online
Article
Text
id pubmed-5892027
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-58920272018-04-19 Olanzapine versus aprepitant for the prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients receiving doxorubicin-cyclophosphamide regimen: A prospective, nonrandomized, open-label study Shivaprakash, G. Udupa, Karthik S. Sarayu, V. Thomas, Joseph Gupta, Vishal Pallavi, L. C. Pemminati, Sudhakar Indian J Pharmacol Research Article OBJECTIVE: Despite the guideline-directed therapy, complete absence of nausea was noted only in 33% of breast cancer patients on anthracycline-cyclophosphamide regimen. Hence, we sought to compare the efficacy of aprepitant (APT) versus olanzapine (OLP) in preventing chemotherapy-induced nausea and vomiting (CINV) in breast cancer patients on doxorubicin-cyclophosphamide regimen. PATIENTS AND METHODS: A prospective, open-label, nonrandomized study was conducted at the Department of Oncology. Eighty-three patients completed the study with 43 in the APT group and 40 in OLP group. Data about nausea and vomiting were collected using Multinational Association of Supportive Care in Cancer Antiemesis Tool (MAT). The severity of nausea and vomiting was assessed by the MAT and Common Terminology Criteria for Adverse Events (CTCAE) version 4.03, respectively. RESULTS: Complete response (no emesis and no rescue medication) was achieved in 81% of the patients in APT group and 85% in the OLP group in the acute period (P = 0.661); 74% of patients in APT group and 85% in OLP group had no nausea during the same period (P = 0.233). Among the OLP patients who had nausea, 67% had moderately severe and 33% had Severe grade, and in the APT group, severity was equally distributed in mild, moderate, and severe grades. Among the patients who had vomiting, severe (CTCAE) vomiting was noticed in 81% of patients who were treated with APT compared to 50% in OLP group. CONCLUSION: OLP was found to be an equally effective alternative to APT in the antiemetic prophylaxis of CINV in breast cancer patients receiving chemotherapy with doxorubicin-cyclophosphamide regimen. Medknow Publications & Media Pvt Ltd 2017 /pmc/articles/PMC5892027/ /pubmed/29674800 http://dx.doi.org/10.4103/ijp.IJP_846_16 Text en Copyright: © 2018 Indian Journal of Pharmacology http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
spellingShingle Research Article
Shivaprakash, G.
Udupa, Karthik S.
Sarayu, V.
Thomas, Joseph
Gupta, Vishal
Pallavi, L. C.
Pemminati, Sudhakar
Olanzapine versus aprepitant for the prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients receiving doxorubicin-cyclophosphamide regimen: A prospective, nonrandomized, open-label study
title Olanzapine versus aprepitant for the prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients receiving doxorubicin-cyclophosphamide regimen: A prospective, nonrandomized, open-label study
title_full Olanzapine versus aprepitant for the prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients receiving doxorubicin-cyclophosphamide regimen: A prospective, nonrandomized, open-label study
title_fullStr Olanzapine versus aprepitant for the prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients receiving doxorubicin-cyclophosphamide regimen: A prospective, nonrandomized, open-label study
title_full_unstemmed Olanzapine versus aprepitant for the prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients receiving doxorubicin-cyclophosphamide regimen: A prospective, nonrandomized, open-label study
title_short Olanzapine versus aprepitant for the prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients receiving doxorubicin-cyclophosphamide regimen: A prospective, nonrandomized, open-label study
title_sort olanzapine versus aprepitant for the prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients receiving doxorubicin-cyclophosphamide regimen: a prospective, nonrandomized, open-label study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5892027/
https://www.ncbi.nlm.nih.gov/pubmed/29674800
http://dx.doi.org/10.4103/ijp.IJP_846_16
work_keys_str_mv AT shivaprakashg olanzapineversusaprepitantfortheprophylaxisofchemotherapyinducednauseaandvomitinginbreastcancerpatientsreceivingdoxorubicincyclophosphamideregimenaprospectivenonrandomizedopenlabelstudy
AT udupakarthiks olanzapineversusaprepitantfortheprophylaxisofchemotherapyinducednauseaandvomitinginbreastcancerpatientsreceivingdoxorubicincyclophosphamideregimenaprospectivenonrandomizedopenlabelstudy
AT sarayuv olanzapineversusaprepitantfortheprophylaxisofchemotherapyinducednauseaandvomitinginbreastcancerpatientsreceivingdoxorubicincyclophosphamideregimenaprospectivenonrandomizedopenlabelstudy
AT thomasjoseph olanzapineversusaprepitantfortheprophylaxisofchemotherapyinducednauseaandvomitinginbreastcancerpatientsreceivingdoxorubicincyclophosphamideregimenaprospectivenonrandomizedopenlabelstudy
AT guptavishal olanzapineversusaprepitantfortheprophylaxisofchemotherapyinducednauseaandvomitinginbreastcancerpatientsreceivingdoxorubicincyclophosphamideregimenaprospectivenonrandomizedopenlabelstudy
AT pallavilc olanzapineversusaprepitantfortheprophylaxisofchemotherapyinducednauseaandvomitinginbreastcancerpatientsreceivingdoxorubicincyclophosphamideregimenaprospectivenonrandomizedopenlabelstudy
AT pemminatisudhakar olanzapineversusaprepitantfortheprophylaxisofchemotherapyinducednauseaandvomitinginbreastcancerpatientsreceivingdoxorubicincyclophosphamideregimenaprospectivenonrandomizedopenlabelstudy